Literature DB >> 2981855

Respective role of each of the purine N-6 amino groups of 5'-O-triphosphoryladenylyl(2'----5')adenylyl(2----5')adenosine in binding to and activation of RNase L.

J Imai, K Lesiak, P F Torrence.   

Abstract

We have synthesized a series of 2-5A (ppp5'-A2'p5'A2'p5'A) analogs in which each adenosine residue has been sequentially replaced by inosine: viz., ppp5'I2'p5'A2'p5'A, ppp5'A2'p5'I2'p5'A, and ppp5'A2'p5'A2'p5'I. These transformations enabled us to delineate the role of each of the three purine N-6 amino groups of 2-5A in determining oligonucleotide binding to and activation of the 2-5A-dependent endoribonuclease, RNase L. With the RNase L activity of both mouse L cells and human Daudi lymphoblastoid cells, we found that the N-6 amino group of the first adenosine nucleotide residue (from the 5'-terminus) is of crucial importance in determining binding to the endonuclease; however, removal of the N-6 amino moieties of the second or third adenosine nucleotide residues resulted in only a minimal decrease in binding to the endonuclease. On the other hand, conversion of the third adenosine residue to inosine effected a dramatic (10,000-fold compared to 2-5A) loss in ability to activate the nuclease; however, execution of the same N-6 amino group conversion at either the first or second adenosine residue did not cause a major change in nuclease activation ability when the accompanying decreased endonuclease binding was considered. These results clearly demonstrate that the N-6 amino group of the first adenosine residue of 2-5A is critical in RNase L binding whereas the N-6 amino function of the third adenosine residue of 2-5A is crucial for the activation of RNase L.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981855

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Recognition of 2',5'-linked oligoadenylates by human ribonuclease L: molecular dynamics study.

Authors:  Kamil Maláč; Ivan Barvík
Journal:  J Mol Model       Date:  2014-03-16       Impact factor: 1.810

2.  8-Methyladenosine-substituted analogues of 2-5A: synthesis and their biological activities.

Authors:  Y Kitade; Y Nakata; K Hirota; Y Maki; A Pabuccuoglu; P F Torrence
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

3.  Direct evidence for translational regulation by leader RNA and Tat protein of human immunodeficiency virus type 1.

Authors:  D N SenGupta; B Berkhout; A Gatignol; A M Zhou; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

4.  Chemical synthesis and biological activities of analogues of 2',5'-oligoadenylates containing 8-substituted adenosine derivatives.

Authors:  M Kanou; H Ohomori; H Takaku; S Yokoyama; G Kawai; R J Suhadolnik; R Sobol
Journal:  Nucleic Acids Res       Date:  1990-08-11       Impact factor: 16.971

5.  Structural basis for recognition of 2',5'-linked oligoadenylates by human ribonuclease L.

Authors:  Nobutada Tanaka; Masayuki Nakanishi; Yoshio Kusakabe; Yoshikuni Goto; Yukio Kitade; Kazuo T Nakamura
Journal:  EMBO J       Date:  2004-09-23       Impact factor: 11.598

6.  Targeting RNA for degradation with a (2'-5')oligoadenylate-antisense chimera.

Authors:  P F Torrence; R K Maitra; K Lesiak; S Khamnei; A Zhou; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

7.  Accumulation of 2',5'-oligoadenylates in encephalomyocarditis virus-infected mice.

Authors:  W G Hearl; M I Johnston
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

8.  A study of the interferon antiviral mechanism: apoptosis activation by the 2-5A system.

Authors:  J C Castelli; B A Hassel; K A Wood; X L Li; K Amemiya; M C Dalakas; P F Torrence; R J Youle
Journal:  J Exp Med       Date:  1997-09-15       Impact factor: 14.307

Review 9.  The 2-5A system: modulation of viral and cellular processes through acceleration of RNA degradation.

Authors:  M R Player; P F Torrence
Journal:  Pharmacol Ther       Date:  1998-05       Impact factor: 12.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.